October 29, 2026
On Tuesday, several of the wealthiest and most influential T1D stakeholders, including the Helmsley Charitable Trust, emailed an open letter calling for Aaron Kowalski to be replaced as Breakthrough T1D's Chief Executive Officer (CEO). The letter is linked in full at the bottom of this report.
The letter is the latest development from the unfortunate story that JDCA broke to the public on June 5, titled “Power Grab at the T1D Fund.” The article revealed that Breakthrough T1D unilaterally and summarily fired several T1D Fund board members, including its chairman, and changed the operating agreement to remove the T1D Fund’s arm's-length operational independence.
Many saw this move as a coup d'état. Breakthrough T1D leadership has argued that these changes will improve the T1D Fund's performance (which it had previously upheld as an example of excellence), but this also left a deep divide in the T1D community. As a result of the rift, tens of millions of dollars pledged to the T1D Fund were returned.
We are now five months along, and the wound is open and as wide as ever. Breakthrough T1D has not yet fixed it, and there does not seem to be real progress toward a solution. Meanwhile, this distracts profoundly from the truly important work of advancing a cure.
Ultimately, for Breakthrough T1D, the responsibility for continuing or fixing the rift rests with its CEO, Aaron Kowalski, and the International Board of Directors (IBOD), to whom he reports. Kowalski has yet to fix the rift, and in our view, after five months, the Board of Directors must now decide whether to accept this status or change it.
The typical T1D donor, who writes checks, dances at galas, and attends walks to fuel these organizations, deserves better. This needs to get fixed so we can all move forward together.
Breakthrough T1D Serves the Whole Community
Breakthrough T1D is arguably the most influential T1D nonprofit with global reach. A publicly supported entity, it serves the entire T1D community. As JDCA has pointed out many times, part of its unique role and ability is to bring different points of view and capabilities together to better the lives of those living with T1D today.
This highly visible, divisive, ongoing battle with key T1D stakeholders—individuals with the capacity to invest substantially in T1D—is interfering with the core mission and the pursuit of a T1D cure. It is only a matter of time before this emotionally draining distraction begins to erode public trust and internal performance, if it has not already.
It Has Gone on Too Long
The rift has now gone on for five months. That is much too long.
The open letter notes that Breakthrough T1D has refused to start an independent third-party investigation into how this all started. This request does not seem inappropriate; the refusal raises questions.
There have also been a number of amendments to the governing documents for the T1D Fund that have been written and rewritten in the past year (Amendments 5-7). JDCA has asked for full copies of these documents so we can compare and contrast them objectively. These requests have been refused, and the documents are being treated like a trade secret—even though Breakthrough T1D and the T1D Fund are public charities.
We believe full transparency is the best course of action.
We Want These Mega Donors Engaged with T1D
Together, the eight people who signed this open letter are remarkable for their capacity to fund T1D research and their many years of service to T1D. Each has been deeply involved with T1D for decades, generously giving both money and personal time. Collectively, they control through estates, trusts, and endowments roughly $20 billion.
The Helmsley Charitable Trust has been the largest private source of funding for T1D research over the past decade. Since grantmaking began in 2008, Helmsley has given roughly $1.5B to T1D-focused initiatives. As a private trust, it can allocate its money to any public initiative its trustees choose, and it continues to choose T1D. They are the giant in the room; we are lucky to have them.
It is counterproductive for these mega-donors and Breakthrough T1D to be adversaries. We believe this fence must be fixed without delay.
The CEO and Board of Directors are Responsible
Ultimately, the CEO, Aaron Kowalski, and the IBOD are responsible for addressing this issue. After five months with no progress, responsibility shifts more heavily to the Board of Directors to decide whether to preserve the status quo or force a change.
The IBOD is led by Chairperson Karen Jordan. When the story originally broke, Jordan had not yet begun her term. Now, well into her tenure, she faces a major issue that has not receded, whether she wanted it or not.
The IBOD has a fiduciary duty to its donors and supporters, and to everyone impacted by T1D, to lead Breakthrough T1D in finding a lasting solution. The main jobs of a board are to ensure the organization stays on mission, review major strategic direction changes, and optimize executive leadership. All three jobs are being challenged in the open letter. The Board must openly debate, discuss, and assess the situation at hand and ensure the organization it oversees addresses these challenges fully and directly.
CEO Stay or Go?
The Board must review and decide whether the current CEO, Aaron Kowalski, should remain in his position or whether it is time for change. Kowalski, who earns over $1 million per year and is the 7th highest-paid disease-focused nonprofit CEO, is also the longest-tenured Breakthrough T1D CEO since 2000, having served seven years.
The open letter, signed by eight former T1D Fund leaders, calls for Kowalski's removal and replacement. The letter argues this is necessary to heal the rift in the T1D community—a deeply unfortunate position.
The International Board of Directors now has a clear responsibility to discuss, review, and debate this. They should not shortchange this and must accept that this is not naturally fading away like old news. We hope the Board is driven by doing the right thing for everyone living with T1D, and nothing else. A strong Breakthrough T1D and fixing this rift benefit everyone.
T1D Fund Leaders' Oct. 27th Open Letter: Access Here
